References

O
Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV coinfection. JAMA. 2015;313(12):1232-1239.
Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014;161(9):634-638.
Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A. Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet. 2016;55(2):197-208.
Owens DK, Davidson KW, Krist AH, et al. US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020. doi:10.1001/jama.2020.1123.
P
Page EE, Nelson M. Hepatitis C and sex. Clin Med (Lond). 2016;16(2):189-192.
Pageaux GP, Nzinga CL, Ganne N, Ganne N. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infect Dis. 2022;22(1):94. doi:10.1186/s12879-022-07076-0 .
Pakianathan M, Whittaker W, Lee M, et al. Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics. HIV Med. 2018;19(7):485-490. doi:10.1111/hiv.12629.
AASLD/IDSA HCV guidance panel, Recommendations for testing, managing, and treating hepatitis C website. Published 2017. Accessed June 13, 2017. 2017. Available at: http://hcvguidelines.org/.
Papaluca T, Roberts SK, Strasser SI, et al. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. Clin Infect Dis. 2020:ciaa1318. Online ahead if print. doi:10.1093/cid/ciaa1318.
Papaluca T, Roberts SK, SI S, et al. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. Clin Infect Dis. 2021;73(9):e3288-e3295. doi:10.1093/cid/ciaa1318.
Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2018;67(2):492-504. doi:10.1002/hep.29505.
Patel S, Martin MT, Flamm SL. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. Liver Int. 2021;41(12):3024–3027. doi:doi:10.1111/liv.15075.
Patel S, Andres J, Qureshi K. An unexpected interaction between sofosbuvir/ledipasvir and atorvastatin and colchicine causing rhabdomyolysis in a patient with impaired renal function. Case Rep Med. 2016;2016:3191089.
Pavone P, Tieghi T, d'Ettorre G, et al. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016;22(462):e461-463.
Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology. 2002;36(5 Suppl 1):S65-S73.
Pawlotsky J-M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70-86.
Pearlman B, Perrys M, Hinds A. Sofosbuvir/velpatasvir/voxilaprevir for previous treatment failures with glecaprevir/pibrentasvir in chronic hepatitis C infection. Am J Gastroenterol. 2019;114(9):1550-1552.
Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Barbara M, Licata A, Craxi A, Camma C, eds. Gastroenterology. 2016;150(1):145-155.e4.
Petta S, Camma C, DiMarco V, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int. 2011;31:507-515.
Petta S, Camma C, di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Alessi N, Cabibi D, Caldarella R, et al., eds. Am J Gastroenterol. 2008;103(5):1136-1144.
Top